Translational Research Cancer Center Consortium Inc

Analysis

Translational Research Cancer Center Consortium Inc is a registered charity in United States, based in Pittsburgh, PA. It received its IRS tax-exemption ruling in February 2021, 5 years ago. Its declared purposes cover diseases, disorders and medical disciplines, which this site groups under health and saving lives. The IRS classifies it as a publicly supported organisation (gross receipts test) under section 501(c)(3), and contributions to it are listed as tax-deductible.

In the financial year ending December 2023, Translational Research Cancer Center Consortium Inc reported income of $115k and spending of $124k, spending 108% of what it took in. Across the 2 years on record, from December 2022 to December 2023, income grew from $95k to $115k (+21%), an average of +21% a year. The sharpest change came in the year to December 2023, when income rose by 21%. Over the whole period it spent 87% of the income it received.

Among 40,470 United States charities whose main cause is health and saving lives and that reported income, Translational Research Cancer Center Consortium Inc sits at the 30th percentile: it is larger than about 30% of them. Against every charity in United States with reported income it ranks in the 41st percentile, and in the 38th percentile within PA. Charities of a similar size with the same main cause include Prosalud Inc ($115k), Helping Haitian Children Inc ($115k) and Arbor Housing Associates ($115k).

At year end it held assets of $92k against liabilities of $0, net assets of $92k.